Pfizer’s latest copycat could put the squeeze on Roche — again
Pfizer $PFE is barreling forward on its plans to recreate Roche’s stalwart cancer drugs, announcing positive data this morning for its Rituxan copycat called PF-05280586. Considering Roche’s $RHHBY recent backlash to biosimilar competition, it’s possible that Pfizer will continue to poke the rather litigious bear.
Like you’d want to see from a biosimilar, PF-05280586’s trial met its primary endpoint and showed equivalence in overall response rate for patients with CD20-positive follicular lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.